(GC Biopharma)

<이미지를 클릭하시면 크게 보실 수 있습니다>

South Korea’s GC Biopharma Corp. announced Friday that it has signed a collaborative agreement with Kanaph Therapeutics to co-develop bispecific antibody-drug conjugates (ADC) for cancer treatment.

The agreement includes an option clause allowing GC Biopharma to participate in joint development if Kanaph’s bispecific ADC candidate meets predefined criteria agreed upon by both companies.

Details such as option requirements, the overall scale of the agreement, and target indications were not disclosed.

Bispecific ADCs are therapeutic agents targeting specific markers expressed in various solid tumors, offering potential treatments for a wide range of cancer patients.

“This collaboration marks an important step in developing innovative therapies for the oncology market, where unmet medical needs remain high,” said Jeong Jae-uk, head of R&D at GC Biopharma.

“We aim to develop differentiated bispecific ADC therapies to provide new treatment opportunities for patients,” said Kanaph CEO Lee Byung-chul.